Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRN NYSE:JNJ NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$57.29-1.9%$57.21$52.93▼$94.85$10.99B0.171.76 million shs1.74 million shsJNJJohnson & Johnson$163.65+0.4%$154.29$140.68▼$169.99$393.87B0.418.14 million shs9.76 million shsVRTXVertex Pharmaceuticals$459.81-0.7%$449.49$377.85▼$519.88$118.08B0.411.42 million shs975,143 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-1.39%+3.71%-3.18%-32.33%JNJJohnson & Johnson0.00%+4.32%+8.54%+3.95%+4.52%VRTXVertex Pharmaceuticals0.00%-1.93%+2.54%-5.99%-5.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMRNBioMarin Pharmaceutical4.9892 of 5 stars4.43.00.03.33.92.54.4JNJJohnson & Johnson4.7678 of 5 stars2.34.04.23.93.41.71.9VRTXVertex Pharmaceuticals4.7144 of 5 stars3.35.00.03.34.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRNBioMarin Pharmaceutical 2.75Moderate Buy$93.7863.70% UpsideJNJJohnson & Johnson 2.57Moderate Buy$172.875.63% UpsideVRTXVertex Pharmaceuticals 2.54Moderate Buy$511.7111.29% UpsideCurrent Analyst Ratings BreakdownLatest BMRN, VRTX, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025JNJJohnson & JohnsonPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight7/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $176.007/17/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $185.007/17/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $190.007/17/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$164.00 ➝ $167.007/17/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$161.00 ➝ $175.007/17/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$171.00 ➝ $176.007/15/2025BMRNBioMarin PharmaceuticalWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$95.007/14/2025BMRNBioMarin PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$108.00 ➝ $113.007/14/2025VRTXVertex PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$515.00 ➝ $517.007/10/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRNBioMarin Pharmaceutical$2.85B3.85$3.25 per share17.65$29.69 per share1.93JNJJohnson & Johnson$90.63B4.34$13.11 per share12.48$29.69 per share5.51VRTXVertex Pharmaceuticals$11.02B10.71N/AN/A$63.72 per share7.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRNBioMarin Pharmaceutical$426.86M$2.6921.3013.140.7917.76%11.34%8.95%8/4/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3517.5014.782.0825.00%33.07%13.16%N/AVRTXVertex Pharmaceuticals-$535.60M-$3.92N/A26.26N/A-8.91%-3.36%-2.42%8/4/2025 (Confirmed)Latest BMRN, VRTX, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025BMRNBioMarin Pharmaceutical$1.02N/AN/AN/A$761.51 millionN/A8/4/2025Q2 2025VRTXVertex Pharmaceuticals$4.24N/AN/AN/A$2.90 billionN/A7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.203.18%N/A55.61%64 YearsVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest BMRN, VRTX, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRNBioMarin Pharmaceutical0.105.523.49JNJJohnson & Johnson0.491.261.03VRTXVertex Pharmaceuticals0.012.652.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRNBioMarin Pharmaceutical98.71%JNJJohnson & Johnson69.55%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBMRNBioMarin Pharmaceutical0.85%JNJJohnson & Johnson0.16%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRNBioMarin Pharmaceutical3,040191.78 million190.15 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableVRTXVertex Pharmaceuticals6,100256.80 million256.28 millionOptionableBMRN, VRTX, and JNJ HeadlinesRecent News About These CompaniesLindbrook Capital LLC Purchases 5,202 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 20 at 9:01 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 20 at 2:54 AM | marketbeat.comAustralianSuper Pty Ltd Sells 91,132 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 19 at 11:04 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by South Dakota Investment CouncilJuly 19 at 10:39 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Lifted by Atle Fund Management ABJuly 19 at 9:13 AM | marketbeat.com3 Top Growth Stocks to Buy in the Second Half of 2025July 19 at 5:45 AM | fool.comMystic Asset Management Inc. Invests $970,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 11:36 AM | marketbeat.comNwam LLC Sells 1,436 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 11:12 AM | marketbeat.comDiversify Advisory Services LLC Purchases 827 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 11:09 AM | marketbeat.comC WorldWide Group Holding A S Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 10:27 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Raised by Jennison Associates LLCJuly 18 at 9:29 AM | marketbeat.comCwm LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 4:42 AM | marketbeat.com2,000 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Retirement Planning Co of New England Inc.July 17 at 9:41 AM | marketbeat.comVictory Capital Management Inc. Sells 11,261 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 17 at 6:51 AM | marketbeat.comWhat is William Blair's Forecast for VRTX FY2025 Earnings?July 17 at 3:31 AM | americanbankingnews.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItJuly 16, 2025 | zacks.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarJuly 16, 2025 | zacks.comTriasima Portfolio Management inc. Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16, 2025 | marketbeat.comWelch & Forbes LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16, 2025 | marketbeat.comGrandfield & Dodd LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16, 2025 | marketbeat.comSegall Bryant & Hamill LLC Has $25.61 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingJNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is NowBy Thomas Hughes | July 16, 2025View JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is NowBMRN, VRTX, and JNJ Company DescriptionsBioMarin Pharmaceutical NASDAQ:BMRN$57.29 -1.08 (-1.85%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$57.74 +0.45 (+0.79%) As of 07/18/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Johnson & Johnson NYSE:JNJ$163.65 +0.67 (+0.41%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$163.84 +0.19 (+0.12%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Vertex Pharmaceuticals NASDAQ:VRTX$459.81 -3.46 (-0.75%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$464.10 +4.30 (+0.93%) As of 07/18/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
